Difference between revisions of "Team:EPFL"

Line 37: Line 37:
 
                     <h3 class="heading h3">What is CAPOEIRA ?</h3>
 
                     <h3 class="heading h3">What is CAPOEIRA ?</h3>
 
                     <div class="text-center mt-4">
 
                     <div class="text-center mt-4">
−
                         <p class="lead lh-180">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be divided into the following parts:</p>
+
                         <p class="lead lh-180">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of its therapy. Immunooncological approaches to treatment are becoming ever more important, with immunotherapy harnessing the immune system's existing weapons in the fight against malignancy. The project that the 2018 EPFL iGEM team presents is focused on developing new techniques for treating melanoma, the deadliest form of skin cancer, by providing a set of tools to identify promising targets, rapidly manufacture an array of corresponding vaccines, and detect potential cancer relapse all on a personalized basis. The project is exhaustive and can be divided into the following parts:</p>
 
                     </div>
 
                     </div>
 
                 </div>
 
                 </div>

Revision as of 21:49, 13 September 2018

iGEM EPFL 2018

CAPOEIRA

Cancer Personalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of its therapy. Immunooncological approaches to treatment are becoming ever more important, with immunotherapy harnessing the immune system's existing weapons in the fight against malignancy. The project that the 2018 EPFL iGEM team presents is focused on developing new techniques for treating melanoma, the deadliest form of skin cancer, by providing a set of tools to identify promising targets, rapidly manufacture an array of corresponding vaccines, and detect potential cancer relapse all on a personalized basis. The project is exhaustive and can be divided into the following parts:

Detection

Detection of cancer patient specific tumor mutations and neoantigens

Vaccine

Expression of the neoantigens and the adjuvant using encapsulin

Immune response

Maturation of dendritic cells and T-cells

Follow up

Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA